医学
耐受性
血压
去神经支配
抵抗性高血压
临床试验
重症监护医学
人口
内科学
药物治疗
心脏病学
不利影响
环境卫生
作者
Simone Fezzi,Gianluca Castaldi,Maddalena Widmann,Federico Marin,Flavio Ribichini
出处
期刊:PubMed
日期:2021-03-01
卷期号:22 (3 Suppl 1): 17S-24S
被引量:1
摘要
Improved and durable control of hypertension is a global priority for healthcare providers and policymakers. Despite all the efforts, hypertension is still misdiagnosed in half of hypertensive patients and poor drug adherence, reaching half of drug-treated patients, represents the major cause of uncontrolled hypertension. Initial studies on renal denervation (RDN) for the treatment of uncontrolled resistant hypertension produced conflicting results. A new generation of randomized clinical trials has shown promising results with new-generation devices in various hypertensive populations. From uncontrolled-resistant hypertension, the target population for RDN has moved to difficult-to-treat or resistant hypertensive patients. The selection process should take into account not only blood pressure values and the global cardiovascular risk profile, but also drug adherence and tolerability and patient preferences. The following is a state-of-the-art review of current studies and an analysis of the characteristics of hypertensive patients that could benefit from RDN.
科研通智能强力驱动
Strongly Powered by AbleSci AI